Symbiotec Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹280 crore and net profit of ₹52 crore for the September 2026 quarter.
Symbiotec Pharma (NSE: SYMBIOTEC) closed at ₹1,598.60 on 20 Nov 2026. Its market capitalisation is ₹10,272 crore and it trades at 69.5 times earnings.
Symbiotec is a research-driven, science- based pharmaceutical and biotechnology company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients (APIs). It has evolved from a Lab-Scale Steroid manufacturer into a fully integrated global platform.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.